MYLIP Polyclonal Antibody
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-9674R |
| Product Name | MYLIP Polyclonal Antibody |
| Applications |
WB
IHC-P
IF(IHC-P)
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human MYLIP |
| Immunogen Range | 51-150/445 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 29116 |
| Swiss Prot | Q8WY64 |
| Subcellular location | Cell membrane |
| Synonyms | MIR; IDOL; E3 ubiquitin-protein ligase MYLIP; Inducible degrader of the LDL-receptor; Myosin regulatory light chain interacting protein; MYLIP; BZF1; BM-023; PP5242 |
| Background | E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. |
| Application Dilution | |
| WB | 1:300-5000 |
| IHC-P | 1:200-400 |
| IF(IHC-P) | 1:50-200 |